Xencor Highlights Antibody Innovations at Upcoming Conferences for Cancer Treatment Advancement

Xencor Showcases Innovative Antibody Development at Upcoming Conferences

Xencor, Inc., a clinical-stage biopharmaceutical company, is poised to highlight its advancements in engineered antibodies for cancer and other serious diseases at several upcoming investor conferences. The first of these events is the Piper Sandler 36th Annual Healthcare Conference, scheduled for December 3, 2024, in New York City, where Xencor's management will present at 2:00 p.m. ET. This presentation is expected to delve into the company’s innovative XmAb® technology, which facilitates minor modifications to protein structures, thereby creating new therapeutic approaches. The following day, on December 4, Xencor will participate in the 7th Annual Evercore HealthCONx Conference in Coral Gables, Florida, presenting at 3:50 p.m. ET.

The XmAb® platform has gained recognition for its potential to transform treatment paradigms, with over 20 candidates currently in clinical development. This technology not only enhances the efficacy of therapeutic antibodies but also broadens the scope of diseases that can be targeted. By making strategic modifications to protein structures, Xencor's approach allows for the development of therapies that can overcome resistance mechanisms in cancer treatment, thereby improving patient outcomes. The company’s commitment to advancing its pipeline reflects a dedication to innovation that is critical in the rapidly evolving biopharmaceutical landscape.

In addition to the clinical potential of its XmAb-derived medicines, Xencor's collaborations with established pharmaceutical partners further illustrate its capability to bring these therapies to market. Several XmAb-based treatments are already available through strategic alliances, demonstrating the practical application of its technology. As Xencor prepares for these conferences, it not only aims to attract investor interest but also seeks to educate stakeholders about the transformative potential of its engineered antibodies in addressing critical healthcare challenges.

Xencor invites interested parties to join the live webcasts of both presentations, which will be available on the company’s website under the “Events & Presentations” section. Replays of the sessions will be accessible for at least 30 days post-event. As the company continues to push the boundaries of antibody engineering, it remains focused on enhancing treatment options for patients facing serious health conditions. For more information on Xencor’s initiatives and pipeline, stakeholders can visit their official website at www.xencor.com.